These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
209 related articles for article (PubMed ID: 12354344)
1. Pharmacologic treatment for detrusor overactivity. Lai HH; Boone TB; Appell RA Curr Urol Rep; 2002 Oct; 3(5):365-72. PubMed ID: 12354344 [TBL] [Abstract][Full Text] [Related]
2. Treatment of overactive bladder: the Antimuscarinic Clinical Effectiveness Trial. Appell RA Curr Urol Rep; 2002 Oct; 3(5):343-4. PubMed ID: 12354340 [No Abstract] [Full Text] [Related]
3. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Abrams P; Freeman R; Anderström C; Mattiasson A Br J Urol; 1998 Jun; 81(6):801-10. PubMed ID: 9666761 [TBL] [Abstract][Full Text] [Related]
4. Tolterodine, a new antimuscarinic drug for treatment of bladder overactivity. Guay DR Pharmacotherapy; 1999 Mar; 19(3):267-80. PubMed ID: 10221366 [TBL] [Abstract][Full Text] [Related]
5. Detrol LA and Diropan XL for overactive bladder. Med Lett Drugs Ther; 2001 Apr; 43(1101):28. PubMed ID: 11283473 [No Abstract] [Full Text] [Related]
6. Tolterodine once-daily in treatment of the overactive bladder. Peters KM; Huang RR Urology; 2001 Nov; 58(5):829-32. PubMed ID: 11711378 [No Abstract] [Full Text] [Related]
7. Clinical experiences with tolterodine. Nilvebrant L Life Sci; 2001 Apr; 68(22-23):2549-56. PubMed ID: 11392625 [TBL] [Abstract][Full Text] [Related]
8. The newer antimuscarinic drugs: bladder control with less dry mouth. Appell RA Cleve Clin J Med; 2002 Oct; 69(10):761, 765-6, 768-9. PubMed ID: 12371799 [TBL] [Abstract][Full Text] [Related]
9. Treatment of overactive bladder with once-daily extended-release tolterodine or oxybutynin: the antimuscarinic clinical effectiveness trial (ACET). Sussman D; Garely A Curr Med Res Opin; 2002; 18(4):177-84. PubMed ID: 12201616 [TBL] [Abstract][Full Text] [Related]
10. Pharmacotherapy of the overactive bladder and advances in drug delivery. Cannon TW; Chancellor MB Clin Obstet Gynecol; 2002 Mar; 45(1):205-17. PubMed ID: 11862073 [No Abstract] [Full Text] [Related]
11. Treatment of the overactive bladder with tolterodine, a new muscarinic receptor antagonist. Messelink EJ BJU Int; 1999 Mar; 83 Suppl 2():48-52. PubMed ID: 10210605 [No Abstract] [Full Text] [Related]
12. Tolterodine use for symptoms of overactive bladder. Ruscin JM; Morgenstern NE Ann Pharmacother; 1999 Oct; 33(10):1073-82. PubMed ID: 10534221 [TBL] [Abstract][Full Text] [Related]
13. Is extended-release oxybutynin (Ditropan XL) or tolterodine (Detrol) more effective in the treatment of an overactive bladder? Hartnett NM; Saver BG J Fam Pract; 2001 Jul; 50(7):571. PubMed ID: 11485700 [No Abstract] [Full Text] [Related]
14. Tolterodine for overactive bladder. Med Lett Drugs Ther; 1998 Oct; 40(1038):101-2. PubMed ID: 9813595 [No Abstract] [Full Text] [Related]
15. The effects of reformulation: improved therapeutic index. MacDiarmid S; Sandage BW; Malhotra BK Curr Urol Rep; 2008 Nov; 9(6):465-71. PubMed ID: 18947511 [TBL] [Abstract][Full Text] [Related]
16. Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. Drutz HP; Appell RA; Gleason D; Klimberg I; Radomski S Int Urogynecol J Pelvic Floor Dysfunct; 1999; 10(5):283-9. PubMed ID: 10543335 [TBL] [Abstract][Full Text] [Related]
17. Muscarinic receptor antagonists in the treatment of overactive bladder. Chapple CR Urology; 2000 May; 55(5A Suppl):33-46; discussion 50. PubMed ID: 10767450 [TBL] [Abstract][Full Text] [Related]